Enhancement effect under high-glucose conditions on U46619-induced spontaneous phasic contraction in mouse portal vein.
The effect of the thromboxane A(2) analog 9,11-dideoxy-11alpha, 9alpha-epoxymethanoprostaglandin F(2alpha) (U46619) on spontaneous phasic contractions in the mouse portal vein was studied. U46619 induced concentration-dependent (1-100 nM) increases in amplitude, frequency, and contractile period (ON-time) of the contraction. Both amplitude and ON-time were enhanced significantly under high-glucose (HG; 4-fold greater than normal) conditions. This hyperactivation may be associated with portal vein dysfunction in diabetes. However, the mechanisms remain unclear. HG enhanced the U46619-induced accumulation of endogenous diacylglycerol (DG). Phospholipase C inhibition suppressed accumulation under normal conditions; however, this suppression was not observed under HG conditions. The HG-induced enhancement of U46619-induced contraction was inhibited by protein kinase C (PKC) inhibition. This finding indicated that accumulated DG might increase PKC activity. Activated PKC stimulated DG kinase activation as a feedback mechanism. DG kinase inhibition also suppressed the HG-induced enhancement of contraction. Increased myo-inositol incorporation was detected under HG conditions, indicating an acceleration of phosphatidylinositol (PI) turnover. This acceleration was inhibited by PKC and DG kinase inhibitors. These findings indicated that HG treatments increased DG synthesis derived from incorporated glucose, PKC, and DG kinase activation. These responses induce hyperactivation of the amplitude and contractile period of contraction mediated by acceleration of PI turnover. This series of responses may be involved in the dysfunction of the portal vein under the HG conditions occurring with diabetes.
Nobe
Koji
K
Department of Pharmacology, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan. kojinobe@pharm.showa-u.ac.jp
Sakai
Yasushi
Y
Nobe
Hiromi
H
Takashima
Junko
J
Paul
Richard J
RJ
Momose
Kazutaka
K
D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology*; D000818:Animals; D001011:Aorta / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D002352:Carrier Proteins / Q000494:pharmacology; D019852:Diacylglycerol Kinase / Q000378:metabolism; D015237:Dinoprost / Q000494:pharmacology; D004347:Drug Interactions; D005947:Glucose / Q000494:pharmacology*; D007294:Inositol / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins; D051379:Mice; D009638:Norepinephrine / Q000494:pharmacology; D011169:Portal Vein / Q000187:drug effects* / Q000502:physiology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D014316:Tritium; D014661:Vasoconstriction / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D001786:Blood Glucose; D002352:Carrier Proteins; D047908:Intracellular Signaling Peptides and Proteins; D014662:Vasoconstrictor Agents; C015482:protein kinase modulator; D014316:Tritium; D007294:Inositol; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D015237:Dinoprost; D019852:Diacylglycerol Kinase; D011493:Protein Kinase C; D005947:Glucose; D009638:Norepinephrine